Statement of Purpose: Diabetes mellitus affects approximately 350 million people, leading to the death of about 4.6 million people in the world. 20-30% of patients with diabetes develop peripheral vascular disease (PVD), among which 25% require amputation, causing a decrease in quality of life. Standard cares of PVD such as stenting are often invasive, so demand for noninvasive treatment is rising. Method that may fulfill such needs is a protein therapy that revives the blood flow in ischemic area. Previously, we explored the use of transmembrane stem cell factor (tmSCF) as a therapeutic protein for restoring blood flow at ischemic area. We found a significant higher blood flow recovery after hind limb ischemia surgery when treated with tmSCF proteoliposomes (PLs) and nanodiscs (NDs). In this research, we hypothesize that tmSCFPLs/NDs stimulate bone marrow cells (BMCs) and increase the CD34-CD133+ subpopulation of endothelial progenitor cells (EPCs). Moreover, enhanced mobilization of EPCs to peripheral blood (PB) was confirmed when treated with tmSCFNDs.